Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective single center study assessing rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy

X
Trial Profile

A retrospective single center study assessing rufinamide efficacy and association with phenotype and genotype in children with intractable epilepsy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rufinamide (Primary) ; Antiepileptic drugs; Carbamazepine; Clobazam; Clonazepam; Diazepam; Dipotassium clorazepate; Ethosuximide; Felbamate; Gabapentin; Lacosamide; Lamotrigine; Levetiracetam; Oxcarbazepine; Perampanel; Phenobarbital; Pregabalin; Topiramate; Valproate; Vigabatrin; Zonisamide
  • Indications Encephalopathy; Generalised epilepsy; Lennox-Gastaut syndrome; Myoclonic epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Oct 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top